Reported Saturday, Incyte's Povorcitinib Achieves Up To 57% HiSCR75 And 29% HiSCR100 At Week 54 In Phase 3 STOP-HS Trials, With NDA And MAA Under Regulatory Review

Incyte's Phase 3 STOP-HS trials for povorcitinib showed significant clinical efficacy in patients with moderate to severe hidradenitis suppurativa, with up to 57% achieving HiSCR75 and 29% achieving HiSCR100 at Week 54. The treatment resulted in up to 71.4% of patients reaching HiSCR50 and demonstrated consistent reductions in key inflammatory lesions. The drug is currently under regulatory review with a New Drug Application (NDA) and Marketing Authorization Application (MAA) submitted.